Knight Therapeutics Inc.
GUD.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 368.06M | 322.69M | 296.41M | 275.81M | 268.06M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 368.06M | 322.69M | 296.41M | 275.81M | 268.06M |
| Cost of Revenue | 199.02M | 179.05M | 170.37M | 157.28M | 147.34M |
| Gross Profit | 169.04M | 143.64M | 126.04M | 118.53M | 120.72M |
| SG&A Expenses | 95.49M | 88.93M | 81.58M | 77.74M | 73.52M |
| Depreciation & Amortization | 39.45M | 35.50M | 33.17M | 30.15M | 30.92M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 358.18M | 324.28M | 304.57M | 282.08M | 268.40M |
| Operating Income | 9.88M | -1.59M | -8.16M | -6.28M | -340.00K |
| Income Before Tax | 5.57M | -4.90M | -7.33M | -5.49M | 6.31M |
| Income Tax Expenses | 1.63M | -899.50K | -4.64M | -5.62M | -1.52M |
| Earnings from Continuing Operations | 3.95 | -4.00 | -2.68 | 0.13 | 7.83 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.95M | -4.00M | -2.68M | 130.90K | 7.83M |
| EBIT | 9.88M | -1.59M | -8.16M | -6.28M | -340.00K |
| EBITDA | 50.55M | 35.52M | 28.32M | 27.12M | 33.90M |
| EPS Basic | 0.04 | -0.04 | -0.03 | 0.00 | 0.08 |
| Normalized Basic EPS | 0.04 | -0.03 | -0.05 | -0.05 | 0.00 |
| EPS Diluted | 0.03 | -0.05 | -0.04 | -0.01 | 0.07 |
| Normalized Diluted EPS | 0.04 | -0.03 | -0.05 | -0.05 | 0.00 |
| Average Basic Shares Outstanding | 397.08M | 398.27M | 399.46M | 400.94M | 402.64M |
| Average Diluted Shares Outstanding | 398.08M | 399.23M | 400.31M | 401.78M | 403.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |